← Evidence library

BIB_175

Long GV et al. Adjuvant Dabrafenib + Trametinib in Stage III BRAF-Mutated Melanoma (COMBI-AD). NEJM 2017;377(19):1813–1823. PMID 28891408. RFS HR 0.51 at 5-yr; 5-yr RFS plateau ~52%. BRAF V600+ adjuvant alternative to ICI. [Tasks: 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

18

Identifiers

PMID:28891408

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_175/findings.md (research corpus). This page is a short context summary — not individualised medical advice.